

UPDATED COVID-19 VACCINE SCHEDULES – 12/13/22

Updated: 12/13/22

Pfizer COVID-19 Vaccination Schedule

NDSU CENTER FOR IMMUNIZATION RESEARCH AND EDUCATION

	Months →				
Age & Indication	0	1	2	3	4
Pfizer for 6 months - 4 years (including for moderately/severely immunocompromised)	1st dose ^a	2nd dose ^{a, b} (3-8 weeks after 1st dose)		3rd dose - Pfizer Bivalent Vaccine ^a (8 weeks after 2nd dose)	
Pfizer for ≥5 years	1st dose	2nd dose ^{b, c} (3-8 weeks after 1st dose)		Bivalent Booster ^{d, e} (≥2 months after primary series OR previous monovalent booster)	
Pfizer 5-11 years moderately/severely immunocompromised	1st dose	2nd dose ^c (3 weeks after 1st)	3rd dose ^c (≥4 weeks after 2nd)		Bivalent Booster ^{d, e} (≥2 months after primary series OR previous monovalent booster)
Pfizer ≥12 years moderately/severely immunocompromised	1st dose	2nd dose ^c (3 weeks after 1st)	3rd dose ^c (≥4 weeks after 2nd)		Bivalent Booster ^{d, e} (≥2 months after primary series OR previous monovalent booster)
	Primary Series			Booster Dose	

- a. The previously authorized 3-dose Pfizer-BioNTech primary series for children ages 6 months–4 years has been revised as follows: a monovalent Pfizer-BioNTech vaccine is administered for the first and second doses, followed by 1 bivalent Pfizer-BioNTech vaccine as the third primary series dose, at least 8 weeks after the second monovalent primary series dose. A booster dose is not authorized for children in this age group who receive a Pfizer-BioNTech 3-dose primary series, including children who previously received a 3-dose monovalent Pfizer-BioNTech primary series.
- b. An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.
- c. In general, the same COVID-19 monovalent vaccine product (Pfizer-BioNTech, Moderna, Novavax) should be used for all doses in the primary series. In exceptional situations when the previous product cannot be determined/not available or if a person is unable to complete a series with the same COVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days).
- d. For bivalent booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary based on age and primary series product.
- e. Monovalent boosters are no longer authorized for this age group.

Updated: 12/13/22

Moderna COVID-19 Vaccination Schedule

NDSU CENTER FOR IMMUNIZATION RESEARCH AND EDUCATION

	Months →				
Age & Indication	0	1	2	3	4
Moderna 6 months - 4 years	1st dose	2nd dose ^{a, b} (4-8 weeks after 1st dose)		Moderna Bivalent Booster ^c (≥2 months after primary series OR previous monovalent booster)	
Moderna for ≥5 years	1st dose	2nd dose ^{a, b} (4-8 weeks after 1st dose)		Bivalent Booster ^{c, d} (≥2 months after primary series OR previous monovalent booster)	
Moderna 6 months - 4 years moderately/severely immunocompromised	1st dose	2nd dose ^a (4 weeks after 1st)	3rd dose ^a (4 weeks after 2nd)		
Moderna ≥5 years moderately/severely immunocompromised	1st dose	2nd dose ^a (4 weeks after 1st)	3rd dose ^a (4 weeks after 2nd)		Bivalent Booster ^{c, d} (≥2 months after primary series OR previous monovalent booster)
	Primary Series			Booster	

- a. In general, the same COVID-19 monovalent vaccine product (Pfizer-BioNTech, Moderna, Novavax) should be used for all doses in the primary series. In exceptional situations when the previous product cannot be determined/not available or if a person is unable to complete a series with the same COVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days).
- b. An 8-week interval between the first and second primary series doses of Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. A shorter interval (3 weeks for Novavax and Pfizer-BioNTech; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.
- c. Monovalent boosters are no longer authorized for this age group.
- d. For bivalent booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary based on age and primary series product.

Novavax COVID-19 Vaccination Schedule

	Months →				
Age & Indication	0	1	2	3	4
Novavax ≥12 years	1st dose	2nd dose ^a (3-8 weeks after 1st dose)		Bivalent Booster ^{b, c} (≥2 months after primary series OR previous monovalent booster)	
Novavax ≥12 years moderately/severely immunocompromised	1st dose	2nd dose ^a (≥3 weeks after 1st dose)		Bivalent Booster ^{b, c} (≥2 months after primary series OR previous monovalent booster)	
	Primary Series			Booster	

a. In general, the same COVID-19 monovalent vaccine product (Pfizer-BioNTech, Moderna, Novavax) should be used for all doses in the primary series. In exceptional situations when the previous product cannot be determined/not available or if a person is unable to complete a series with the same COVID-19 vaccine due to a contraindication any age-appropriate mRNA COVID-19 vaccine may be used (administer at a minimum interval of 28 days).
 b. For booster vaccination, any homologous or heterologous age-appropriate mRNA vaccine can be used. Recommendations vary based on age and primary series product. People ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series if they are unable (i.e., contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.
 c. Monovalent boosters are no longer authorized for this age group

Johnson & Johnson (Janssen) COVID-19 Vaccination Schedule

	Months →			
Age & Indication	0	1	2	3
≥18 years	1 dose (J&J)		Bivalent Booster ^{a, b} (>2 months after primary series OR previous monovalent booster)	
>18 years Moderately or severely immunocompromised	1 dose (J&J)	1 dose - mRNA ^a (4 weeks after primary dose)		Bivalent Booster ^{a, b} (>2 months after primary series OR previous monovalent booster)
	Primary Series		Booster Dose	

ALERT: Janssen (Johnson & Johnson) COVID-19 Vaccine should ONLY be used in certain limited situations. See the CDC's clinical considerations for greater detail: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a>

a. People who are moderately or severely immunocompromised ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive a second (additional) dose using a monovalent mRNA vaccine and 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech). The primary series dose and the additional dose are separated by at least 4 weeks. The bivalent mRNA booster dose is administered at least 2 months after the additional dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.
 b. People ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive 1 bivalent mRNA booster dose (i.e., Moderna or Pfizer-BioNTech) at least 2 months after completion of the primary series dose (for people who have not received any booster doses), or at least 2 months after the last monovalent booster dose.
 c. Monovalent boosters are no longer authorized for this age group

For more information on COVID-19 vaccine schedules:

CDC Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>

NDHHS COVID-19 Vaccine Information: <https://www.hhs.nd.gov/public-health-information/coronavirus/covid-19-vaccine-information>